Browse the corpus

©2013 UpToDate ® Print Email WHO classification of acute myeloid leukemia (AML) AML with recurrent genetic abnormalities AML with t(8;21)(q22;q22), RUNX1-RUNX1T1 AML with inv(16)(p13q22) or t(16;16)(p13;q22), CEFB-MYH11 Acute promyelocytic leukemia with t(15;17)(q22;q12), PML-RARA AML with t(9;11)(p22;q23); MLLT3-MLL AML with t(6;9)(p23;q34); DEK-NUP214 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 AML with mutated NPM1 (provisional entity) AML with mutated CEBPA (provisional entity) AML with myelodysplasia-related features Therapy related AML and MDS AML, not otherwise specified* AML with minimal differentiation AML without maturation AML with maturation Acute myelomonocytic leukemia Acute monoblastic/acute monocytic leukemia Acute erythroid leukemia (erythroid/myeloid and pure erythroleukemia variants) Acute megakaryoblastic leukemia Acute basophilic leukemia Acute panmyelosis with myelofibrosis Myeloid sarcoma Myeloid proliferations related to Down syndrome Transient abnormal myelopoiesis Myeloid leukemia associated with Down syndrome Blastic plasmacytoid dendritic cell neoplasm MDS: myelodysplastic syndromes; MPD: myeloproliferative diseases. * The entities included in this group are defined almost identically as the corresponding entity in the French-American-British (FAB) classification. Adapted from: Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008. p.29. Permission granted from Harris NL and Vardiman JW.